Condensed Consolidated Statements of Operations (Unaudited) (USD $)	3 Months Ended		6 Months Ended		22 Months Ended	166 Months Ended
	Jun. 30, 2011 Successor	Jun. 30, 2010 Successor	Jun. 30, 2011 Successor	Jun. 30, 2010 Successor	Jun. 30, 2011 Successor	Aug. 31, 2009 Predecessor
Revenue
Product sales	$ 253,274	$ 264,062	$ 461,910	$ 473,132	$ 1,728,220	$ 4,818,994
License fees			0	0	0	260,000
Total revenue	253,274	264,062	461,910	473,132	1,728,220	5,078,994
Cost of sales	125,753	175,916	223,611	276,435	908,307	2,279,335
Gross profit	127,521	88,146	238,299	196,697	819,913	2,799,659
Selling, general and administrative expenses	3,265,344	1,821,330	5,619,727	3,841,243	14,843,664	84,805,520
Research and development expenses	1,601,665	1,473,741	3,218,194	2,666,351	10,527,709	56,269,869
Operating loss	(4,739,488)	(3,206,925)	(8,599,622)	(6,310,897)	(24,551,460)	(138,275,730)
Other income (expense)
Interest income			0	0	1	6,989,539
Reorganization items, net			0	3,303	(69,174)	73,538,984
Other income			0	0	244,479	316,338
Warrant (expense) income	(3,510,552)	1,712,430	(9,806,882)	295,186	(10,591,198)	0
Derivative revaluation (expense)	(1,561,412)	0	(8,182,138)	0	(8,182,138)	0
Interest expense	(283,661)	(203,268)	(557,069)	(400,998)	(1,849,442)	(18,790,218)
Loss from continuing operations before income taxes			(27,145,711)	(6,413,406)	(44,998,932)	(76,221,087)
Income tax benefit			0	0	0	190,754
Loss from continuing operations	(10,095,113)	(1,697,763)	(27,145,711)	(6,413,406)	(44,998,932)	(76,030,333)
Loss from discontinued operations	(6,083)	(12,502)	(18,199)	(29,546)	(79,117)	(41,091,311)
Net loss	(10,101,196)	(1,710,265)	(27,163,910)	(6,442,952)	(45,078,049)	(117,121,644)
Deemed dividend associated with beneficial conversion			0	0	0	(11,423,824)
Preferred stock dividends			0	0	0	(1,589,861)
Net (income)/loss attributable to noncontrolling interest	(26,896)	(1,250)	(46,552)	(16,388)	(113,943)	1,799,523
Net loss attributable to Fibrocell Science, Inc. common shareholders	$ (10,128,092)	$ (1,711,515)	$ (27,210,462)	$ (6,459,340)	$ (45,191,992)	$ (128,335,806)
Per share information:
Loss from continuing operations-basic and diluted	$ (0.32)	$ (0.09)	$ (1.02)	$ (0.37)	$ (2.24)	$ (4.30)
Loss from discontinued operations-basic and diluted			$ 0.00	$ 0.00	$ 0.00	$ (2.32)
Income (loss) attributable to noncontrolling					$ (0.01)	$ 0.10
Deemed dividend associated with beneficial conversion of preferred stock			$ 0.00	$ 0.00	$ 0.00	$ (0.65)
Preferred stock dividends			$ 0.00	$ 0.00	$ 0.00	$ (0.09)
Net loss attributable to common shareholders per common share - basic and diluted	$ (0.32)	$ (0.09)	$ (1.02)	$ (0.37)	$ (2.25)	$ (7.26)
Weighted average number of basic and diluted common shares outstanding	31,825,735	19,468,831	26,557,261	17,678,219	20,097,309	17,678,219